Related Experiment Video

Updated: Nov 13, 2025

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
08:04

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

12.2K

Efficacy of axitinib rechallenge in metastatic renal cell carcinoma

Kotaro Suzuki1, Takuto Hara1, Tomoaki Terakawa1

  • 1Division of Urology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.

International Journal of Urology : Official Journal of the Japanese Urological Association
|March 15, 2021
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.1K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.0K

Related Experiment Videos

Last Updated: Nov 13, 2025

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
08:04

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

12.2K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.1K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.0K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K

Articles linked to this work by shared authors, journal, and citation graph.

Clinical and pathological significance of serum anti-PD-1 autoantibodies in acute-onset and chronic autoimmune hepatitis.

Hepatology international·2026

Porto-Sinusoidal Vascular Disorder-Spectrum Portal Venopathy as a Structural Substrate for Portal Hypertension in Anti-Centromere Antibody-Positive Primary Biliary Cholangitis.

Pathology international·2026

Sex disparities in primary biliary cholangitis: insights from a Japanese multicentre cohort.

Medical molecular morphology·2026

Efficacy and Safety of Enfortumab Vedotin by Trial Eligibility in Advanced Urothelial Carcinoma: A Multicenter Real-World Study.

International journal of urology : official journal of the Japanese Urological Association·2026

Indoleamine 2,3-Dioxygenase 1 as an Adjunctive Histopathological Marker of Cholangitis Activity in Primary Biliary Cholangitis.

Hepatology research : the official journal of the Japan Society of Hepatology·2026

Case Report: Adult-onset diffuse hepatic hemangiomatosis with rapid progression: an autopsy case with diagnostic difficulty.

Frontiers in medicine·2026

Younger Age Is Associated With Slower PSA Decline After Low-Dose-Rate Brachytherapy for Localized Prostate Cancer.

International journal of urology : official journal of the Japanese Urological Association·2026

Treatment-Effect Heterogeneity and a Simple Framework for Estimating Survival Benefit Associated With Local Therapy in Nonmetastatic Advanced Prostate Cancer: A Multicenter KAMU-ON Cohort Study.

International journal of urology : official journal of the Japanese Urological Association·2026

Oncological Outcomes of Neoadjuvant Chemotherapy in High-Risk UTUC: A Multicenter Study.

International journal of urology : official journal of the Japanese Urological Association·2026

Quantitative Evaluation of Pharmacologic Synergy for Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle-Invasive Bladder Cancer: A Copula-Based Secondary Analysis.

International journal of urology : official journal of the Japanese Urological Association·2026

Overactive Bladder Pharmacotherapy and Long-Term Care Needs, Dementia, and Frailty in Older Women.

International journal of urology : official journal of the Japanese Urological Association·2026

Depressive Symptom Severity Is Associated With IPSS and ICIQ-SF Scores but Not Overactive Bladder in Japanese Male Never-Smokers.

International journal of urology : official journal of the Japanese Urological Association·2026

Preventing Weight Regain After Glucagon-Like Peptide‑1 Therapy Discontinuation: A Pilot Randomized Controlled Trial.

Obesity science & practice·2026

Successful Breast-Conserving Surgery Following Dose-Modified Neoadjuvant Chemoimmunotherapy in an 86-Year-Old Patient With Locally Advanced Triple-Negative Breast Cancer: A Case Report.

Clinical case reports·2026

I need it. Without it, I wouldn't have gone, and I do want to go: patient perspectives on the acceptability and appropriateness of two patient-centered interventions to improve adherence to annual lung cancer screening.

Frontiers in health services·2026

Immunosuppressive cell populations as potential drivers of extrinsic immune checkpoint inhibition resistance in clear cell renal cell carcinoma.

Oncology reviews·2026

Development of a risk-stratified follow-up strategy based on early and late recurrence risk factors in locally advanced esophageal squamous cell carcinoma after definitive chemoradiotherapy.

Frontiers in oncology·2026

Multimodality therapy for stage IB3 cervical cancer with a delayed diagnosis at 21 weeks of gestation: from neoadjuvant chemotherapy to adjuvant chemoradiotherapy-a case report.

Frontiers in medicine·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us